Clostridioides difficile infection: microbe-microbe interactions and live biotherapeutics
Clostridioides difficile is a gram-positive, spore-forming, obligate anaerobe that infects the colon. C. difficile is estimated to cause nearly half a million cases in the United States annually, with about 29,000 associated deaths. Unfortunately, the current antibiotic treatment is not ideal. Whi...
Main Author: | Ruojun Wang |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-05-01
|
Series: | Frontiers in Microbiology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fmicb.2023.1182612/full |
Similar Items
-
The development of live biotherapeutics against Clostridioides difficile infection towards reconstituting gut microbiota
by: Yongrong Zhang, et al.
Published: (2022-12-01) -
Patient Perception of Route of Rectal Administration of Live Biotherapeutic Product for Recurrent Clostridioides difficile Infection
by: Feuerstadt P, et al.
Published: (2023-08-01) -
Gut microbiota and microbiota-based therapies for Clostridioides difficile infection
by: Teena Chopra, et al.
Published: (2023-01-01) -
Final Results from a Phase 2b Randomized, Placebo-Controlled Clinical Trial of RBX2660: A Microbiota-Based Drug for the Prevention of Recurrent Clostridioides difficile Infection
by: Erik R. Dubberke, et al.
Published: (2022-12-01) -
Faecal transplantation and Clostridioides difficile infection
by: Knežević Darija A., et al.
Published: (2021-01-01)